Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 183

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

DNA hypermethylation within TERT promoter upregulates TERT expression in cancer

Open access
Lee, Donghyun D., Leão, Ricardo, Komosa, Martin, Gallo, Marco, Zhang, Cindy H., Lipman, Tatiana, Remke, Marc, Heidari, Abolfazl, Nunes, Nuno Miguel, Apolónio, Joana D., Price, Aryeh J., De Mello, Ramon Andrade, Dias, João S., Huntsman, David, Hermanns, Thomas, Wild, Peter J., Vanner, Robert, Zadeh, Gelareh, Karamchandani, Jason, Das, Sunit, Taylor, Michael D., Hawkins, Cynthia E., Wasserman, Jonathan D., Figueiredo, Arnaldo, Hamilton, Robert J., Minden, Mark D., Wani, Khalida, Diplas, Bill, Yan, Hai, Aldape, Kenneth, Akbari, Mohammad R., Danesh, Arnavaz, Pugh, Trevor J., Dirks, Peter B., Castelo-Branco, Pedro, Tabori, Uri · 2018 · Journal of Clinical Investigation

Abstract

Replicative immortality is a hallmark of cancer cells governed by telomere maintenance. Approximately 90% of human cancers maintain their telomeres by activating telomerase, driven by the transcriptional upregulation of telomerase reverse transcriptase (TERT). Although TERT promoter mutations (TPMs) are a major cancer-associated genetic mechanism of TERT upregulation, many cancers exhibit TERT upregulation without TPMs. In this study, we describe the TERT hypermethylated oncological region (THOR), a 433-bp genomic region encompassing 52 CpG sites located immediately upstream of the TERT core promoter, as a cancer-associated epigenetic mechanism of TERT upregulation. Unmethylated THOR repressed TERT promoter activity regardless of TPM status, and hypermethylation of THOR counteracted this repressive function. THOR methylation analysis in 1,352 human tumors revealed frequent (>45%) cancer-associated DNA hypermethylation in 9 of 11 (82%) tumor types screened. Additionally, THOR hypermethylation, either independently or along with TPMs, accounted for how approximately 90% of human cancers can aberrantly activate telomerase. Thus, we propose that THOR hypermethylation is a prevalent telomerase-activating mechanism in cancer that can act independently of or in conjunction with TPMs, further supporting the utility of THOR hypermethylation as a prognostic biomarker.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci121303

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 183

Metadata

Authors
Lee, D. D., Leão, R., Komosa, M., Gallo, M., Zhang, C. H., Lipman, T., Remke, M., Heidari, A., Nunes, N. M., Apolónio, J. D., Price, A. J., De Mello, R. A., Dias, J. S., Huntsman, D., Hermanns, T., Wild, P. J., Vanner, R., Zadeh, G., Karamchandani, J., Das, S., Taylor, M. D., Hawkins, C. E., Wasserman, J. D., Figueiredo, A., Hamilton, R. J., Minden, M. D., Wani, K., Diplas, B., Yan, H., Aldape, K., Akbari, M. R., Danesh, A., Pugh, T. J., Dirks, P. B., Castelo-Branco, P., & Tabori, U.
Venue
Journal of Clinical Investigation
Published
2018-12-03
Volume
129
Issue
1
Pages
223-229
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2898125316
Cited by
183
References
5
FWCI
10.69
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.